In Q4 2025, Avoro Capital Advisors held 31 positions worth $9.9B. They initiated 9 new positions and exited 41. Their largest holding was UTHR ($1.3B). Portfolio value grew +35.7% versus the prior quarter.
Frequently asked questions
What stocks did Avoro Capital Advisors own in Q4 2025?
Avoro Capital Advisors held 31 biotech stocks in their 13F portfolio in Q4 2025. Their top positions include UTHR, ASND, MDGL, ARGX, KRYS. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Avoro Capital Advisors's portfolio worth in Q4 2025?
Avoro Capital Advisors's tracked biotech portfolio was worth $9.9B across 31 positions, with total assets under management of approximately $6B. Portfolio values are based on 13F filings with the SEC.
What did Avoro Capital Advisors buy in Q4 2025?
Avoro Capital Advisors initiated 9 new positions in Q4 2025, including CELC, TERN, RVMD, MNMD, PTCT and 4 more. They also increased 10 existing positions.
What did Avoro Capital Advisors sell in Q4 2025?
Avoro Capital Advisors fully exited 41 positions in Q4 2025, including ALNY, BCYC, CERE, PMVP, ROIV and 36 more. They also trimmed 6 existing positions.
Is Avoro Capital Advisors a biotech fund?
Biotech specialist fund (formerly Venbio Select Advisor) that takes concentrated positions in clinical and commercial-stage companies. Aghazadeh, a biochemist, is known for activist-style engagement and has served on multiple biotech boards to drive value creation.
Want AI analysis, insider signals, and catalyst overlays for Avoro Capital Advisors?
View latest Avoro Capital Advisorsportfolio →